GlassScriptPhysician profile
Tami B Caldwell
NPI 1457427858
$12,660.95
in general payments reported to CMS, 2019-2025
26 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,755 · 2022: $2,524 · 2023: $2,312 · 2024: $2,615 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,355 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,354.63 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,119.36 | 2021-2025 | |
| Janssen Biotech, INC. | $2,670.83 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,463.95 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Genzyme Corporation | $907.72 | 2022-2025 | |
| Ardelyx, INC. | $643.09 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $570.69 | 2021-2025 | Gattex, Entyvio |
| Celgene Corporation | $490.38 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $426.74 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $330.15 | 2021-2025 | Linzess |
| Merck Sharp & Dohme LLC | $320.40 | 2022-2024 | Dificid, Zerbaxa |
| Nestle Healthcare Nutrition INC. | $308.85 | 2021-2023 | |
| Braintree Laboratories, INC. | $215.37 | 2021-2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $208.50 | 2024-2025 | Vowst, Zenpep |
| Pfizer INC. | $146.64 | 2022-2025 | |
| Madrigal Pharmaceuticals | $146.50 | 2025 | Rezdiffra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $143.45 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $134.54 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $89.82 | 2021-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $77.63 | 2021-2025 | |
| Redhill Biopharma INC. | $50.58 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $49.08 | 2021 | |
| Evoke Pharma, INC. | $43.54 | 2021-2025 | |
| Intra-Sana Laboratories | $37.04 | 2021 | |
| Qol Medical, LLC | $29.67 | 2023 | Sucraid |
| Orphalan INC | $18.27 | 2024 | Cuvrior |
| E.R. Squibb & Sons, L.L.C. | $18.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.